Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas



Similar documents
Saturation Biopsy vs. 3D Spatial Biopsy vs. Free Hand Ultrasound biopsy for Targeted Prostate Cancer Therapies

OBJECTIVES By the end of this segment, the community participant will be able to:

The Diagnosis of Cancer in the Pathology Laboratory

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

The 4Kscore blood test for risk of aggressive prostate cancer

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports

An Introduction to PROSTATE CANCER

Historical Basis for Concern

Something Old, Something New.

Update on Mesothelioma

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

Saturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Prostate cancer is the most common cause of death from cancer in men over age 75. Prostate cancer is rarely found in men younger than 40.

Understanding your pathology report

BREAST CANCER PATHOLOGY

CONTENTS: WHAT S IN THIS BOOKLET

Early Prostate Cancer: Questions and Answers. Key Points

Advances in Diagnostic and Molecular Testing in Prostate Cancer

Does my patient need more therapy after prostate cancer surgery?

A918: Prostate: adenocarcinoma

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

PSA Screening for Prostate Cancer Information for Care Providers

Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

A New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Diagnostic Challenge. Department of Pathology,

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Primary -Benign - Malignant Secondary

RENAL CANCER PATHOLOGY WHAT REALLY MATTERS? STEWART FLEMING UNIVERSITY OF DUNDEE

Rare Thoracic Tumours

Individual Prediction

SRO Tutorial: Prostate Cancer Treatment Options

Report series: General cancer information

Testing for Prostate Cancer

ATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Newly Diagnosed Prostate Cancer: Understanding Your Risk

How to report Upper GI EMR/ESD specimens

Medullary Renal Cell Carcinoma Case Report

A 70-year old Man with Pleural Effusion

Role of MRI in the Diagnosis of Prostate Cancer, A Proposal

بسم هللا الرحمن الرحيم

Us TOO University Presents: Understanding Diagnostic Testing

Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Robert Bristow MD PhD FRCPC

Beyond the PSA: Genomic Testing in Localized Prostate Cancer

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

PSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.

AFTER DIAGNOSIS: PROSTATE CANCER Understanding Your Treatment Options

Evaluation of Diagnostic and Screening Tests: Validity and Reliability. Sukon Kanchanaraksa, PhD Johns Hopkins University

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Prostate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.

SEMESTER VI 3 RD YEAR PATHOLOGY KIDNEY TUMORS

The develpemental origin of mesothelium

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14

Carcinosarcoma of the Ovary

YOUR LUNG CANCER PATHOLOGY REPORT

Bard: Prostate Cancer Treatment. Bard: Pelvic Organ Prolapse. Prostate Cancer. An overview of. Treatment. Prolapse. Information and Answers

Cytopathology Case Presentation #8

PROTOCOL OF THE RITA DATA QUALITY STUDY

The TV Series. INFORMATION TELEVISION NETWORK

Guidelines for reporting histopathology of cervical carcinoma

A new score predicting the survival of patients with spinal cord compression from myeloma

GENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.

The 4Kscore blood test for risk of aggressive prostate cancer

Practical Effusion Cytology

HEALTH NEWS PROSTATE CANCER THE PROSTATE

Understanding Metastatic Disease

Breast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach

Pseudohyperplastic Prostatic Adenocarcinoma: A Case Report and Review of the Literature +

LifeProtect. Cancer Cover. For Intermediary Use Only

Technical Advices for Prostate Needle Biopsy Under Transrectal Ultrasound Guidance

CT and MRI features of the Pathologic Subtypes of Papillary Renal Cell Carcinoma. Melissa Price, MD Aoife Kilcoyne, MD Mukesh G.

ALTHOUGH excellent accounts have been published in recent years of

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

Questions to ask my doctor: About prostate cancer

Transcription:

International Urology and Nephrology 28 (1), pp. 73-77 (1996) Intraobserver and Interobserver Reproducibility of WHO and Gleason Histologic Grading Systems in Prostatic Adenocarcinomas $. O. OZDAMAR,* $. SARIKAYA,** L. YILDIZ,* M. K. ATILLA,** 13. KANDEMIR,* S. YILDIZ** Departments of *Pathology and **Urology, Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey (Accepted October 16, 1995) In this study a total of 96 patients with prostatic carcinoma were evaluated retrospectively. Sections prepared from paraffin blocks were examined and all cases were scored according to the World Health Organization (WHO) and Gleason grading systems. We investigated intraobserver and interobserver reproducibility of two grading systems in prostatic adenocarcinomas. In our study the intraobserver reproducibilities of the WHO and Gleason systems were 75.0% and 78.1%, respectively. The interobserver reproducibilities of the WHO and Gleason grading systems were 60.4% and 70.8%, respectively. While there was no difference between intraobserver and interobserver variations in the Gleason system (p>0.05), there was significant difference between intraobserver and interobserver variations in the WHO system (p<o.05). Introduction Carcinoma of the prostate is the most common form of cancer in men and the second leading cause of cancer-related deaths. Determining the biologic behaviour of the tumour is very important for deciding the best method of therapy. Histopathological grading and staging are the most frequently used methods for predicting the biological behaviour of prostatic carcinomas. Recognizing the relationship between histologic appearance of prostatic tumours and clinical evaluation, many investigators have been searching for histologic classifications that fulfil the requirements of prognostic accuracy, reliability and objectivity [1-5]. A limitation of most grading systems is that histologic grading is a subjective procedure. The inconsistency in histologic grading may invalidate its use in treatment decision. In this way, the reproducibility has the same significance as the predictive character of prognosis. It is necessary to find the most reliable method before histologic grades are incorporated routinely into the diagnosis of prostatic carcinoma. Although at least 30 grading systems have been proposed, few of them have been shown to be reproducible. Today, the most widely used grading systems are those of the World Health Organization (WHO) and Gleason (see Table 1) [3, 5]. WHO accepted that the grading system might be based on the degree of nuclear anaplasia (nuclear grades), and the degree of glandular differentiation VSP, Utrecht Akad~miai Ktadt, Budapest

74 Ozdamar et al.: Grading systems of prostatic cancer Table 1 Comparison of adenocarcinoma of prostate grading systems WHO system Grade 1 Well-differentiated Tumours consisting of simple small or simple large glands 2 Moderately differentiated Those with complex glands, fused glands or glands in glands 3 Poorly differentiated Those with few glands 4 Undifferentiated Those with columns and cords or solid sheets Gleason system Pattern (Gleason grade: sum of primary and secondary patterns) 1 Very well-differentiated, small, closely packed, uniform glands in essentially circumscribed masses 2 Similar to Pattern 1, but with moderate variation in size and shape of glands and more atypia in the individual cells, still essentially circumscribed, but more loosely arranged 3 Similar to Pattern 2, but marked irregularity in size and shape of glands, with tiny glands or individual cells invading stroma away from circumscribed masses, or solid cords and masses with easily identifiable glandular differentiation within most of them; may be papillary or cribriform 4 Large clear cells growing in a diffuse pattern resembling "hypernephroma"; may also show gland formation 5 Very poorly differentiated tumours; usually solid masses or diffuse growth with little differentiation into glands. In cases showing more than one pattern, the second pattern was classified and recorded (histologic grades). Nuclear anaplasia was defined as variations of nuclear size, shape, and chromatin distribution and the character of the nucleoli (grades 1-3). The two parameters, nuclear grades and histologic grades, individually or combined with the clinical stage, have been found to provide a good prognostic index [4, 5]. The Gleason system recognizes five histologic patterns of prostatic adenocarcinoma. Any given tumour may exhibit any of these patterns or a combination; therefore, in this grading system the two most predominant patterns and secondary patterns are added to arrive at a grade ranging from 2 to 10 [4, 6, 7]. In the present study, the ina'aobserver and interobserver reproducibilities of the WHO grading system based on the degree of glandular differentiation, and the Gleason scoring system were examined. Material and methods A set of histological sections of 96 prostatic carcinomas stained with haematoxylin and eosin was graded twice by one and the same pathologist on two different occasions. Another pathologist who did not know the results of

Ozdamar et al.: Grading systems of prostatic cancer 75 the first also examined the same sections. They used the grading systems of tumour differentiation as described by WHO and Gleason. The intraobserver and interobserver variations were computed. The data were analyzed by the test for significant difference between two proportions for paired data. A p value less than 0.05 was considered significant. Results Distribution of the patients by grade for each grading system is shown in Table 2. The overall intraobserver reproducibility of the WHO system was 75.0% and of the Gleason grading system 78.1%. The interobserver reproducibilities of the WHO and Gleason grading systems were 60.4% and 70.8%, respectively. There was no difference between intraobserver and interobserver variations in the Gleason system (p>0.05), but there was a significant difference between intraobserver and interobserver variation in the WHO system (p<0.05). While there was no difference in intraobserver variations (p>0.05), there was a significant difference in interobserver variations between the WHO and the Gleason grading systems (p<0.05). Table 2 Results of Gleason and WHO grading systems inlraobserver and interobserver reproducibility Gleason First Reproducibility Reproducibility observation of second of second (n) observation (%) observer (%) Grade 2 0 Grade 3 10 80.0 60.0 Grade 4 7 57.1 42.8 Grade 5 25 72.0 68.0 Grade 6 29 86.2 75.8 Grade 7 16 68.7 75.0 Grade 8 3 100.0 100.0 Grade 9 5 100.0 80.0 Grade 10 1 lo0.0 100.0 WHO Total 96 78.1 70.8 Grade 1 11 81.8 63.6 Grade 2 43 81.3 72.0 Grade 3 34 61.7 44.1 Grade 4 8 87.5 62.5 Total 96 75.0 60.4

76 Ozdamar et al.: Grading systems of prostatic cancer Discussion Although staging is important in determining the treatment of patients with prostatic adenocarcinoma, it does not always predict the biologic behaviour of the tumour. Grading has been advocated as a method of improving our ability to predict the tumour's biologic behaviour. Unfortunately, the reproducibility and clinical significance of grading have been suspect [7-9]. These shortcomings are well recognized and are emphasized by different pathologists, In addition, there are obvious limitations in the accuracy of grading based on the small amount of tissue available from needle biopsies of the prostate. Nonetheless, developing morphologic parameters to assist in determining prognosis and treatment for adenocarcinoma of the prostate are important goals for both pathologists and clinicians [3-5]. We preferred the WHO grading system based on the degree of glandular differentiation, because of its similarity to the Broders grading system which is commonly used in other carcinomas. When the WHO grading system was used, the vast majority of cases (80.2%) in our series were either grade 2 or grade 3, similar to the results of Brawn et al. [3]. We found an intraobserver reproducibility rate of 75.0%, and an interobserver reproducibility rate of 60.4%. The intraobserver reproducibility rate was better than the interobserver reproducibility rate (p<0.05). The major conflicts were in grades 3 and 4. The experience of the pathologist may influence observer variations and bias may be minimized as much as possible by choosing pathologist who were involved in uropathology for the same period. On the other hand, definition of pathological features may change from one pathologist to another [5-7, 8]. These problems raise questions as to the value of a grading system in close cooperation between different pathologists. When the Gleason grading system was used, the majority of cases (30.2%) in our series were grade 6, similar to Gleason's study [2]. We found intraobserver reproducibility rate to be 78.1% which is better than the reproducibility found by other workers [9-11]. Employing his own system, Gleason estimated his intraobserver reproducibility rate to be 80% which is similar to our result. Although our interobserver reproducibility rate was lower than the intraobserver reproducibility rate, the difference was statistically not significant (p>0.05). In interobserver evaluations there was a significant difference between the WHO and the Gleason systems (p<0.05). It seems that agreement among pathologists in the Gleason grading system is greater than expected by chance, and reproducibility rates in interobserver evaluation are higher in the Gleason system as compared to the WHO system. In the absence of a gold standard, the value of a histological indicator can be measured by examining the inter- and intraobserver reproducibility rates. Those items with poor agreement cannot be regarded as reliable indicators and cannot be used for making a decision. A histological grading system showing higher intra- and interobserver reproducibility rates seems ideal. In addition, if there is no statistically significant difference between inter- and intraobserver

Ozdamar et al.: Grading systems of prostatic cancer 77 reproducibility rates it may be safely used by different pathologists. In this study, we found higher intra- and interobserver reproducibility rates both in the WHO and the Gleason grading systems, but only a comparison of inu'a- and interobserver reproducibility rates was not different in the Gleason grading system. For this reason we suggested that the Gleason grading system was better than the WHO grading system based on the degree of glandular differentiation. Further studies including patients' survival, clinical stage, neuroendocrine differentiation, proliferative index (PCNA/Cyclin reactivity), immunohistochemical analysis (PSA and PSAP) and comparison of these parameters with the histologic grading systems will be helpful in understanding the roles of these grading systems in prostatic adenocarcinomas. Acknowledgements We would like to thank Esin Ozyilkan, M. D. and Naziye Gttrkan, M. S. for their help. References 1. Boring, C. C., Squires, T. S., Tong, T., Montgomery, S.: Cancer statistics. CA Cancer J. Clin., 44, 7 (1994). 2. Gleason, D. F.: Histologic grading of prostate cancer: A perspective. Hum. Pathol., 23, 273 (1992). 3. Brawn, P. N., Ayala, A. G., Von Eschenbach, A. C., Hussey, D. H., Johnson, D. E.: Histologic grading study of prostate adenocarcinoma: The development of a new system and comparison with other methods - A preliminary study. Cancer, 49, 525 (1982). 4. Cintra, M. L., Billis, A.: Histologic grading of prostatic adenocarcinoma: Intraobserver reproducibility of the Mostofi, Gleason and B0cking grading systems. Int. Urol. NephroL, 23, 449 (1991). 5. Mostofi, F,, Sesterhenn, I. A., Davis, C. J.: Pathologist's view of prostatic carcinoma. Cancer Suppl., 71, 906 (1993). 6, Gleason, D. F.: Histologic grading of prostatic carcinoma. In: Bostwick, D. G. (ed.): Pathology of the Prostate. Churchill Livingstone, New York 1990. 7. Sogani, P., Israel, A., Liebennan, P., Lesser, M. L., Whitmore, W. F. Jr.: Gleason grading of prostate cancer: A predictor of survival. Urology, 25, 223 (1985). 8. Schroeder, F, H., Hop, W. C., Bloom, J. H., Mostofi, F. K.: Grading of prostatic carcinoma: Multivariant analysis of prognostic parameters. Prostate, 7, 13 (1985). 9. Gallee, M. P. W,, Ten Kate, F. J. W., Mulder, G.: Histologic grading of prostate carcinoma in prostatectomy specimens: A comparison of prognostic accuracy of five grading systems. Br. J. Urol., 65, 368 (1990). 10. Murphy, G. P., Whitmore, W. F. Jr.: A report of the workshops on the current status of the histologic grading of prostate cancer. Cancer, 44, 1490 (1979). 11. Svanholm, H., Mygind, H.: Prostatic carcinoma reproducibility of histologic grading. Acta Pathol. Microbiol. Scand., 93, 67 (1985).